Table 2.
Characteristics of patients aged 15 to 49 under active follow-up in private care, public primary care and public tertiary care ART programmes during 2012–2017a
| Type of careb | Total (n = 182 285) | |||
|---|---|---|---|---|
| Private carec (n = 140 322) | Public primary carec (n = 39 381) | Public tertiary carec (n = 2582) | ||
| Characteristics at ART initiation | ||||
| Female, n (%) | 93 249 (66.5) | 28 076 (71.3) | 1757 (68.0) | 123 082 (67.5) |
| Median [IQR] age, years | 36 [32–41] | 32 [28–38] | 33 [28–39] | 35 [31–41] |
| Median CD4 cells/μl [IQR] |
254 [135–410] | 193 [107–302] | 162 [87–242] | 238 [127–380] |
| Characteristics at baselined | ||||
| Median years on ART [IQR] | 0.3 [0.0–2.0] | 0.0 [0.0–2.0] | 1.2 [0.0–3.7] | 0.1 [0.0–2.1] |
| Median [IQR] age, years | 38 [33–43] | 34 [29–39] | 36 [30–41] | 37 [32–42] |
| Median CD4 cells/μl [IQR]e | 378 [229–571] | 307 [184–454] | 320 [189–493] | 359 [219–548] |
| CD4 category at baselinee, n (%) | ||||
| 0–99 cells/μl | 11 383 (8.1) | 3381 (8.6) | 265 (10.3) | 15 029 (8.2) |
| 100–199 cells/μl | 14 075 (10.0) | 4480 (11.4) | 358 (13.9) | 18 913 (10.4) |
| 200–349 cells/μl | 30 171 (21.5) | 9224 (23.4) | 668 (25.9) | 40 063 (22.0) |
| 350–499 cells/μl | 26 364 (18.8) | 5864 (14.9) | 456 (17.7) | 32 684 (17.9) |
| ≥500 cells/μl | 40 436 (28.8) | 5519 (14.0) | 563 (21.8) | 46 518 (25.5) |
| Missing | 17 893 (12.8) | 10 913 (27.7) | 272 (10.5) | 29 078 (16.0) |
ART, antiretroviral therapy; IQR, interquartile range.
a
Patients with at least one follow-up visit between 1 January 2012 and 31 December 2017 were included.
b
All values in the table represent medians and interquartile ranges unless otherwise stated.
c
Private care: AfA programme; public primary care: Gugulethu and Khayelitsha programmes; public tertiary care: Tygerberg Hospital.
d
Baseline was defined as 1 January 2012 or date of ART initiation of the patient, whichever came second.
e
The CD4 cell count measurement closest to the baseline date, within a 6-month window (before or after).